Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity
Abstract Cisplatin, one of the most active anticancer agents, is widely used in standard chemotherapy for various cancers. Cisplatin is more poorly tolerated than other chemotherapeutic drugs, and the main dose-limiting toxicity of cisplatin is its nephrotoxicity, which is dose-dependent. Although l...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/71f2c5bdd1594bf081bb9c4162ab9c10 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:71f2c5bdd1594bf081bb9c4162ab9c10 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:71f2c5bdd1594bf081bb9c4162ab9c102021-12-02T15:22:58ZCombination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity10.1038/s41598-020-80853-62045-2322https://doaj.org/article/71f2c5bdd1594bf081bb9c4162ab9c102021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-80853-6https://doaj.org/toc/2045-2322Abstract Cisplatin, one of the most active anticancer agents, is widely used in standard chemotherapy for various cancers. Cisplatin is more poorly tolerated than other chemotherapeutic drugs, and the main dose-limiting toxicity of cisplatin is its nephrotoxicity, which is dose-dependent. Although less toxic methods of cisplatin administration have been established, cisplatin-induced nephrotoxicity remains an unsolved problem. Megalin is an endocytic receptor expressed at the apical membrane of proximal tubules. We previously demonstrated that nephrotoxic drugs, including cisplatin, are reabsorbed through megalin and cause proximal tubular cell injury. We further found that cilastatin blocked the binding of cisplatin to megalin in vitro. In this study, we investigated whether cilastatin could reduce cisplatin-induced nephrotoxicity without influencing the antitumor effects of cisplatin. Nephrotoxicity was decreased or absent in mice treated with cisplatin and cilastatin, as determined by kidney injury molecule-1 staining and the blood urea nitrogen content. Combined with cilastatin, a twofold dose of cisplatin was used to successfully treat the mice, which enhanced the antitumor effects of cisplatin but reduced its nephrotoxicity. These findings suggest that we can increase the dose of cisplatin when combined with cilastatin and improve the outcome of cancer patients.Masashi AritaSatoshi WatanabeNobumasa AokiShoji KuwaharaRyo SuzukiSawako GotoYuko AbeMiho TakahashiMiyuki SatoSatoshi HokariAya OhtsuboSatoshi ShojiKoichiro NozakiKosuke IchikawaRie KondoMasachika HayashiYasuyoshi OhshimaHideyuki KabasawaMichihiro HosojimaToshiyuki KoyaAkihiko SaitoToshiaki KikuchiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Masashi Arita Satoshi Watanabe Nobumasa Aoki Shoji Kuwahara Ryo Suzuki Sawako Goto Yuko Abe Miho Takahashi Miyuki Sato Satoshi Hokari Aya Ohtsubo Satoshi Shoji Koichiro Nozaki Kosuke Ichikawa Rie Kondo Masachika Hayashi Yasuyoshi Ohshima Hideyuki Kabasawa Michihiro Hosojima Toshiyuki Koya Akihiko Saito Toshiaki Kikuchi Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity |
| description |
Abstract Cisplatin, one of the most active anticancer agents, is widely used in standard chemotherapy for various cancers. Cisplatin is more poorly tolerated than other chemotherapeutic drugs, and the main dose-limiting toxicity of cisplatin is its nephrotoxicity, which is dose-dependent. Although less toxic methods of cisplatin administration have been established, cisplatin-induced nephrotoxicity remains an unsolved problem. Megalin is an endocytic receptor expressed at the apical membrane of proximal tubules. We previously demonstrated that nephrotoxic drugs, including cisplatin, are reabsorbed through megalin and cause proximal tubular cell injury. We further found that cilastatin blocked the binding of cisplatin to megalin in vitro. In this study, we investigated whether cilastatin could reduce cisplatin-induced nephrotoxicity without influencing the antitumor effects of cisplatin. Nephrotoxicity was decreased or absent in mice treated with cisplatin and cilastatin, as determined by kidney injury molecule-1 staining and the blood urea nitrogen content. Combined with cilastatin, a twofold dose of cisplatin was used to successfully treat the mice, which enhanced the antitumor effects of cisplatin but reduced its nephrotoxicity. These findings suggest that we can increase the dose of cisplatin when combined with cilastatin and improve the outcome of cancer patients. |
| format |
article |
| author |
Masashi Arita Satoshi Watanabe Nobumasa Aoki Shoji Kuwahara Ryo Suzuki Sawako Goto Yuko Abe Miho Takahashi Miyuki Sato Satoshi Hokari Aya Ohtsubo Satoshi Shoji Koichiro Nozaki Kosuke Ichikawa Rie Kondo Masachika Hayashi Yasuyoshi Ohshima Hideyuki Kabasawa Michihiro Hosojima Toshiyuki Koya Akihiko Saito Toshiaki Kikuchi |
| author_facet |
Masashi Arita Satoshi Watanabe Nobumasa Aoki Shoji Kuwahara Ryo Suzuki Sawako Goto Yuko Abe Miho Takahashi Miyuki Sato Satoshi Hokari Aya Ohtsubo Satoshi Shoji Koichiro Nozaki Kosuke Ichikawa Rie Kondo Masachika Hayashi Yasuyoshi Ohshima Hideyuki Kabasawa Michihiro Hosojima Toshiyuki Koya Akihiko Saito Toshiaki Kikuchi |
| author_sort |
Masashi Arita |
| title |
Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity |
| title_short |
Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity |
| title_full |
Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity |
| title_fullStr |
Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity |
| title_full_unstemmed |
Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity |
| title_sort |
combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/71f2c5bdd1594bf081bb9c4162ab9c10 |
| work_keys_str_mv |
AT masashiarita combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT satoshiwatanabe combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT nobumasaaoki combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT shojikuwahara combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT ryosuzuki combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT sawakogoto combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT yukoabe combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT mihotakahashi combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT miyukisato combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT satoshihokari combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT ayaohtsubo combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT satoshishoji combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT koichironozaki combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT kosukeichikawa combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT riekondo combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT masachikahayashi combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT yasuyoshiohshima combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT hideyukikabasawa combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT michihirohosojima combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT toshiyukikoya combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT akihikosaito combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity AT toshiakikikuchi combinationtherapyofcisplatinwithcilastatinenablesanincreaseddoseofcisplatinenhancingitsantitumoreffectbysuppressionofnephrotoxicity |
| _version_ |
1718387386773143552 |